SAREPTA THERAPEUTICS INC

20 February, 2025

Sarepta Therapeutics Reports Strong Financial Growth and Faces Competition Amid Promising Advances in DMD Treatments

Sarepta Therapeutics, Inc. continues to establish itself as a leader in precision genetic medicine, particularly in the realm of rare diseases such as Duchenne muscular dystrophy (DMD). The company’s ...
Read More

19 February, 2025

Sarepta Therapeutics Faces Competitive Pressure from Solid Biosciences as Financial Outlook Remains Strong with Projected $1.8 Billion Revenue in 2024

Sarepta Therapeutics, a biotechnology leader specializing in precision genetic medicine for rare diseases, is poised for significant growth as it continues to address the pressing needs of patients wi...
Read More

18 February, 2025

Sarepta Therapeutics Reports Strong Financial Outlook and Pipeline Progress Amidst FDA-approved DMD Treatments

Sarepta Therapeutics, Inc. continues to make waves in the biotech industry with its focus on rare diseases, particularly Duchenne muscular dystrophy (DMD). The company’s flagship therapy, Elevidys, ha...
Read More

17 February, 2025

Sarepta Therapeutics Reports Strong Financial Outlook and Robust Pipeline with Elevidys Approval Boosting Revenue Projections

Sarepta Therapeutics, a leader in precision genetic medicine focused on rare diseases, particularly Duchenne muscular dystrophy (DMD), continues to display strong financial momentum and growth prospec...
Read More